Subscribe
vidal_kathi_sv_color_cropped-2-
19 May 2022AmericasMuireann Bolger

USPTO urges Vidal review of Arthrex petition

The  US Patent and Trademark Office (USPTO) has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Medtech
Arthrex petitions Fed Circ again over ‘inferior officers’
13 January 2022   Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew.
Americas
Senators urge USPTO to curb ‘patent thicket’ abuse
9 June 2022   A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.
Americas
Vidal steps up scrutiny of Fintiv rule-based decisions
6 September 2022   Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Medtech
Arthrex petitions Fed Circ again over ‘inferior officers’
13 January 2022   Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew.
Americas
Senators urge USPTO to curb ‘patent thicket’ abuse
9 June 2022   A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.
Americas
Vidal steps up scrutiny of Fintiv rule-based decisions
6 September 2022   Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.

More on this story

Medtech
Arthrex petitions Fed Circ again over ‘inferior officers’
13 January 2022   Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew.
Americas
Senators urge USPTO to curb ‘patent thicket’ abuse
9 June 2022   A bipartisan group of six US senators have asked the US Patent and Trademark Office to address ‘patent thickets’, a tactic that pharmaceutical companies allegedly use to stifle competition.
Americas
Vidal steps up scrutiny of Fintiv rule-based decisions
6 September 2022   Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?